These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 10544761)
1. [Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS)]. Penault-Llorca F; Jacquemier J; Le Doussal V; Voigt JJ Ann Pathol; 1999 Sep; 19(4):280-2. PubMed ID: 10544761 [No Abstract] [Full Text] [Related]
2. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor]. Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693 [No Abstract] [Full Text] [Related]
3. Inconsistency of HER2 test raises questions. Tuma RS J Natl Cancer Inst; 2007 Jul; 99(14):1064-5. PubMed ID: 17623788 [No Abstract] [Full Text] [Related]
4. [Assessment of HER2 status in breast cancer]. Penault-Llorca F; Cayre A Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610 [TBL] [Abstract][Full Text] [Related]
5. Trastuzumab administration associated with change in HER2 status. Dawood S; Resetkova E; Gonzalez-Angulo AM Clin Breast Cancer; 2008 Aug; 8(4):366-9. PubMed ID: 18757266 [TBL] [Abstract][Full Text] [Related]
6. [Her2/neu receptor: one of the basic factors rendering tailored therapy feasible in breast cancer patients]. Kulka J Orv Hetil; 2005 Apr; 146(17):785-90. PubMed ID: 17918634 [TBL] [Abstract][Full Text] [Related]
8. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer. Kurosumi M Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922 [No Abstract] [Full Text] [Related]
10. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. Burstein HJ; Winer EP J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535 [No Abstract] [Full Text] [Related]
11. Trastuzumab in breast cancer. Banna GL; Santoro A N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951 [No Abstract] [Full Text] [Related]
12. Trastuzumab before breast surgery? Large trial says yes but does not quell debate. Rowan K J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626 [No Abstract] [Full Text] [Related]
13. Herceptin (trastuzumab): adjuvant and neoadjuvant trials. Yaal-Hahoshen N; Safra T Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172 [No Abstract] [Full Text] [Related]
14. Saving lives with accurate HER2 testing. Ross JS Am J Clin Pathol; 2010 Aug; 134(2):183-4. PubMed ID: 20660318 [No Abstract] [Full Text] [Related]
15. [Herceptin (trastuzumab)]. Yamashiro H; Toi M Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197 [TBL] [Abstract][Full Text] [Related]
16. Making real progress against breast cancer. Some of the best cancer news this year has been the success of targeted approaches to treating breast cancer. Harv Womens Health Watch; 2005 Oct; 13(2):1-3. PubMed ID: 16320417 [No Abstract] [Full Text] [Related]
17. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492 [TBL] [Abstract][Full Text] [Related]
18. Isolated tumor cells in breast cancer. Sonke GS; Linn SC N Engl J Med; 2009 Nov; 361(20):1995; author reply 1995-6. PubMed ID: 19911470 [No Abstract] [Full Text] [Related]
19. Recent trends of HER-2 testing and trastuzumab therapy for breast cancer. Kurosumi M Breast Cancer; 2009; 16(4):284-7. PubMed ID: 19657709 [TBL] [Abstract][Full Text] [Related]